Facebook
Twitter
Telegram
Report an ErrorMadrigal Pharmaceuticals Financial Ratios 2011-2024 | MDGL
Annual Financial Ratios Madrigal Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-44.3 | -61.0 | -3.9 | -9.1 | -15.1 | -51.0 | -55.0 | -2.9 | -0.4 | -2.7 | -4.3 | -10.5 | -4.7 |
P/S |
- | - | - | 83902.4 | - | - | - | - | - | - | - | 4490.1 | 29.2 |
EPS |
-5.7 | -5.0 | -14.6 | -13.1 | -5.5 | -2.2 | -2.5 | -5.1 | -40.0 | -0.9 | -1.3 | -1.1 | -1 |
EV (Enterprise Value) |
5.1 B | 5.07 B | 993 M | 1.83 B | 1.24 B | 1.62 B | 1.57 B | 62.8 M | 48.3 M | 270 M | 385 M | 606 M | 219 M |
EBITDA per Share |
-5.9 | -4.92 | -14.6 | -13.3 | -6.16 | -2.74 | -2.61 | -4.85 | -18.2 | -29.6 | -42.9 | -35.5 | -32.6 |
EV/EBITDA |
-4.1 | -8.7 | -12.8 | -39.8 | -48.9 | -2.3 | -0.0 | -2.4 | -4.2 | -9.8 | -4.7 | ||
PEG |
-1.08 | -1.61 | -0.09 | -0.36 | 0.1 | -4.05 | -1.1 | -0.04 | -0.01 | -0.09 | 0.22 | 1.75 | 0.62 |
P/B |
12.3 | 26.5 | 4.9 | 7.6 | 3.0 | 3.5 | 9.4 | 2.1 | 0.6 | 3.6 | 7.9 | 8.8 | 15.0 |
P/CF |
-15.3 | -23.3 | -5.2 | -11.6 | -30.3 | -65.6 | -76.3 | -4.4 | -0.4 | -3.0 | -5.0 | -12.1 | -4.6 |
ROE % |
-27.68 | -43.52 | -123.32 | -84.28 | -20.15 | -6.88 | -17.09 | -72.47 | -136.23 | -132.28 | -183.72 | -83.65 | -320.70 |
ROA % |
-17.52 | -23.69 | -88.48 | -70.47 | -18.99 | -6.76 | -16.20 | -64.03 | -100.70 | -85.58 | -94.74 | -60.95 | -111.95 |
ROCE % |
-22.45 | -34.58 | -123.40 | -85.96 | -22.78 | -8.53 | -17.59 | -69.28 | -134.13 | -120.30 | -138.99 | -76.63 | -167.18 |
Current Ratio |
2.7 | 2.2 | 3.5 | 6.1 | 17.5 | 57.5 | 19.1 | 8.6 | 3.8 | 3.2 | 2.9 | 4.3 | 2.7 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Madrigal Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-7.38 | - | -5.34 | -4.69 | -4.23 | - | -4.75 | -4.14 | -3.36 | -3.78 | -3.79 | -3.72 | -3.32 | -3.82 | -3.75 | -3.18 | -2.34 | -1.8 | -1.39 | -1.28 | -0.98 | -0.75 | -0.56 | -0.45 | -0.45 | -0.67 | -0.68 | -0.69 | -0.5 | - | -1.59 | -16.33 | -9.72 | -0.08 | -10.46 | -0.15 | -0.19 | -0.19 | -0.19 | -0.24 | -0.28 | -0.31 | -0.33 | -0.33 | -0.3 | -0.29 | -0.25 | -0.25 | -0.27 | -0.22 | -0.26 | -0.26 | -0.27 |
EBITDA per Share |
-7.59 | - | - | - | -4.3 | - | -4.68 | -4.11 | -3.36 | -3.78 | -3.78 | -3.73 | -3.34 | -3.85 | -3.78 | -3.25 | -2.46 | -1.94 | -1.56 | -1.47 | -1.18 | -0.94 | -0.74 | -0.54 | -0.5 | -0.71 | -0.7 | -0.7 | -0.51 | - | -1.59 | -15 | -3.93 | -0.08 | -3.95 | -0.15 | -0.19 | -0.18 | -0.18 | -0.23 | -0.27 | -0.31 | -0.31 | -0.32 | -0.29 | -0.28 | -0.24 | -0.24 | -0.25 | -0.21 | -0.28 | -0.28 | -0.25 |
ROE % |
-987.83 | -577.91 | -1338.89 | -1656.08 | -1657.86 | -885.12 | -918.04 | -183.92 | -122.02 | -102.73 | -94.45 | -91.74 | -89.39 | -84.28 | -66.30 | -47.29 | -31.59 | -20.15 | -15.90 | -12.54 | -9.16 | -6.88 | -9.11 | -11.91 | -15.14 | -17.09 | -63.65 | -110.26 | -118.28 | -68.50 | -46.96 | 7.91 | -18.77 | -55.14 | -28.30 | -62.63 | -57.57 | -52.65 | -150.25 | -165.46 | -177.67 | -183.72 | -158.65 | -132.76 | -105.82 | -83.65 | -132.22 | -198.43 | -263.58 | -320.70 | -86.19 | -84.62 | -77.17 |
ROA % |
-124.99 | -92.99 | -144.17 | -153.86 | -151.33 | -102.85 | -126.46 | -70.16 | -88.96 | -80.09 | -77.07 | -76.56 | -74.84 | -70.47 | -56.14 | -40.80 | -28.17 | -18.99 | -15.08 | -11.98 | -8.86 | -6.76 | -8.79 | -11.38 | -14.39 | -16.20 | -57.04 | -97.92 | -104.72 | -60.52 | -2958.37 | -3408.17 | -3426.06 | -3452.27 | -574.64 | -99.45 | -92.55 | -85.58 | -90.75 | -94.56 | -96.36 | -94.74 | -86.95 | -77.86 | -68.11 | -60.95 | -68.74 | -84.27 | -99.62 | -111.95 | -30.09 | -29.54 | -26.94 |
ROCE % |
-200.84 | -147.35 | -281.99 | -345.38 | -386.87 | -258.20 | -291.08 | -183.27 | -121.91 | -102.78 | -94.67 | -92.28 | -90.45 | -85.96 | -68.37 | -49.73 | -34.24 | -22.78 | -18.62 | -15.20 | -11.39 | -8.53 | -10.39 | -12.75 | -15.74 | -17.59 | -51.40 | -85.37 | -87.98 | -47.98 | -26.75 | 13.75 | -17.67 | -54.20 | -22.25 | -51.92 | -44.35 | -38.62 | -129.01 | -135.73 | -139.66 | -138.99 | -124.04 | -107.72 | -90.47 | -76.63 | -92.04 | -118.72 | -145.14 | -167.18 | -44.96 | -44.19 | -40.35 |
Current Ratio |
4.7 | 2.7 | 1.1 | 1.5 | 1.8 | 2.2 | 1.1 | - | 2.9 | 3.5 | 4.4 | 5.7 | 6.3 | 6.1 | 6.1 | 6.1 | 6.1 | 17.3 | 17.3 | 17.3 | 17.3 | 57.5 | 57.5 | 57.5 | 57.5 | 19.1 | 19.1 | 19.1 | 19.1 | 8.6 | 8.6 | 8.6 | 8.6 | 0.0 | 0.0 | 3.8 | 3.8 | 2.8 | 2.8 | 2.8 | 2.8 | 2.1 | 2.1 | 2.1 | 2.1 | 3.7 | 3.7 | 3.7 | 3.7 | 1.5 | 1.5 | 1.5 | 1.5 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency